Speaking at the recent inauguration of its new pharmaceutical packaging plant in Jambusar, Gujarat, Kairus Dadachanji, Managing Director of SCHOTT KAISHA, said that the plant will cater to not only the pharma industry but also packaging of vaccines and other biologics.
Mr.Dadachanji adds,"SCHOTT KAISHA has been supplying packaging vials and ampoules to the majority of the Indian vaccine industry, including companies like Serum Institute of India, Zydus Cadila, Bharat Biotech, Panacea Biotec, Shantha Biotechnics, GSK, Chiron and more.Almost 80-90% of the vaccines that are maufactured in India are packaged in SCHOTT KAISHA glass. It is a matter of great honour for us we play a role in the vaccination of millions of children worldwide ".
The Indo-German joint venture, SCHOTT KAISHA is a leading supplier for the pharmaceutical industry offering solution for the entire range of small volume tubular glass parenteral packaging including ampoules, vials, cartridges and sterile prefillable glass syringes.
Today, 70% of the goods manufactured at the plant are for the Indian markets, whereas the rest are exported. The facility will now be able to increase its production capacity by 50%.With the Indian pharmaceutical market growing by approximately 14 to 17 percent per year, this expansion of packaging capabilities has been driven with respect to the by demand from India's prospering middle class.
The primary shareholders of the company include veterans fo the Indian industry such as Mr.Shapoorji Pallonji Mistry, and Mr.Kairus Dadachandji, both of whom own 25% stake and the rest is owned by SCHOTT AG , Germany. In 2008, the international technology group SCHOTT and Kaisha Manufacturers formed the joint venture of SCHOTT KAISHA. Since its merger, SCHOTT KAISHA has garnered over 150 customers in the pharma space and have been growing at a steady rate of 25% YoY. The 50:50 joint venture today employs about 1,600 people in its plants in Daman and Jambusar and its Mumbai office.